Agouron Pharmaceuticals (AGPH) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Henry Niman who wrote (1942)	9/30/1997 3:14:00 PM
From: John Metcalf	of 6136

CNN Headline News ran the same story last night. Dr. Anthony Fauci of NIH was on-camera and said that under real-world conditions, the best results are not obtained due to improper dosing. (Those who have been following the thread for some time might remember that Lee Warzula made the same observation a long time ago.) The great results obtained in clinical trials occurred under conditions that encouraged rigid adherence to dosing schedules. Much has been written about reasons for non-compliance -- too many pills, problems with meal/sleep/work times, difficulties due to side effects, false sense of security coincident with health improvement. It may well be that real-world results will be diffential amongst PI's, dependent on these characteristics. The latest cross-resistance story brings to mind that many PI clinical trials that were restricted to those who had no previous treatment, or limited previous treatment. Resultantly, there has been a lack of data for those with previous anti-retroviral exposure. Further data should become available this week, and will continue to emerge for some time.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next